Downloads: 84

Files in This Item:
File Description SizeFormat 
eLife.65872.pdf2.5 MBAdobe PDFView/Open
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTakahashi, Satoshien
dc.contributor.authorKanai, Akinorien
dc.contributor.authorOkuda, Hiroshien
dc.contributor.authorMiyamoto, Ryoen
dc.contributor.authorKomata, Yosukeen
dc.contributor.authorKawamura, Takeshien
dc.contributor.authorMatsui, Hirotakaen
dc.contributor.authorInaba, Toshiyaen
dc.contributor.authorTakaori-Kondo, Akifumien
dc.contributor.authorYokoyama, Akihikoen
dc.contributor.alternative高橋, 慧ja
dc.contributor.alternative金井, 昭教ja
dc.contributor.alternative奥田, 博史ja
dc.contributor.alternative宮本, 亮ja
dc.contributor.alternative小俣, 洋介ja
dc.contributor.alternative川村, 猛ja
dc.contributor.alternative松井, 啓隆ja
dc.contributor.alternative稲葉, 俊哉ja
dc.contributor.alternative高折, 晃史ja
dc.contributor.alternative横山, 明彦ja
dc.date.accessioned2021-09-07T08:45:59Z-
dc.date.available2021-09-07T08:45:59Z-
dc.date.issued2021-08-
dc.identifier.urihttp://hdl.handle.net/2433/265093-
dc.description白血病を引き起こすタンパク質間相互作用の発見. 京都大学プレスリリース. 2021-08-31.ja
dc.description.abstractLeukemic oncoproteins cause uncontrolled self-renewal of hematopoietic progenitors by aberrant gene activation, eventually causing leukemia. However, the molecular mechanism underlying aberrant gene activation remains elusive. Here, we showed that leukemic MLL fusion proteins associate with the HBO1 histone acetyltransferase (HAT) complex through their trithorax homology domain 2 (THD2) in various human cell lines. MLL proteins associated with the HBO1 complex through multiple contacts mediated mainly by the ING4/5 and PHF16 subunits in a chromatin-bound context where histone H3 lysine 4 tri-methylation marks were present. Of the many MLL fusions, MLL-ELL particularly depended on the THD2-mediated association with the HBO1 complex for leukemic transformation. The C-terminal portion of ELL provided a binding platform for multiple factors including AF4, EAF1, and p53. MLL-ELL activated gene expression in murine hematopoietic progenitors by loading an AF4/ENL/P-TEFb (AEP) complex onto the target promoters wherein the HBO1 complex promoted the association with AEP complex over EAF1 and p53. Moreover, the NUP98-HBO1 fusion protein exerted its oncogenic properties via interaction with MLL but not its intrinsic HAT activity. Thus, the interaction between the HBO1 complex and MLL is an important nexus in leukemic transformation, which may serve as a therapeutic target for drug development.en
dc.language.isoeng-
dc.publishereLife Sciences Publications, Ltden
dc.rights© 2021, Takahashi et al.en
dc.rightsThis article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.en
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/-
dc.subjectResearch Articleen
dc.subjectCancer Biologyen
dc.subjectChromosomes and Gene Expressionen
dc.subjectMLLen
dc.subjectHBO1en
dc.subjectleukemiaen
dc.subjectepigenetic regulatorsen
dc.subjectENLen
dc.subjectAF4en
dc.titleHBO1-MLL interaction promotes AF4/ENL/P-TEFb-mediated leukemogenesisen
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleeLifeen
dc.identifier.volume10-
dc.relation.doi10.7554/eLife.65872-
dc.textversionpublisher-
dc.identifier.artnume65872-
dc.addressTsuruoka Metabolomics Laboratory, National Cancer Center; Department of Hematology and Oncology, Kyoto University Graduate School of Medicineen
dc.addressDepartment of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima Universityen
dc.addressTsuruoka Metabolomics Laboratory, National Cancer Centeren
dc.addressTsuruoka Metabolomics Laboratory, National Cancer Centeren
dc.addressTsuruoka Metabolomics Laboratory, National Cancer Centeren
dc.addressIsotope Science Center, The University of Tokyoen
dc.addressDepartment of Molecular Laboratory Medicine, Faculty of Life Sciences, Kumamoto Universityen
dc.addressDepartment of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima Universityen
dc.addressDepartment of Hematology and Oncology, Kyoto University Graduate School of Medicineen
dc.addressTsuruoka Metabolomics Laboratory, National Cancer Center; Department of Hematology and Oncology, Kyoto University Graduate School of Medicine; Division of Hematological Malignancy, National Cancer Center Research Instituteen
dc.identifier.pmid34431785-
dc.relation.urlhttps://www.kyoto-u.ac.jp/ja/research-news/2021-08-31-0-
dcterms.accessRightsopen access-
datacite.awardNumber16H05337-
datacite.awardNumber19H03694-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16H05337/-
datacite.awardNumber.urihttps://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-19H03694/-
dc.identifier.eissn2050-084X-
jpcoar.funderName日本学術振興会ja
jpcoar.funderName日本学術振興会ja
jpcoar.awardTitleMLL白血病の分子基盤に基づく新規治療法の開発ja
jpcoar.awardTitleMLL白血病発症メカニズムの統一的理解ja
Appears in Collections:Journal Articles

Show simple item record

Export to RefWorks


Export Format: 


This item is licensed under a Creative Commons License Creative Commons